CAR T-cell Therapy Articles

Top Centers Exploring JCAR017 for Non-Hodgkin Lymphoma
After demonstrating early success in acute lymphoblastic leukemia, CAR T-cell therapies are now expanding into all areas of hematologic malignancies, including non-Hodgkin lymphoma.
Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL
Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.
Study Identifies Potential Biomarkers for CAR T-Cell Therapy Response in CLL
A study presented at the 2017 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.
Novel CAR T-cell Combos on Horizon for Hematologic Malignancies
Novel combination approaches are being explored that hope to capitalize on the high rates of complete remissions seen with CAR T-cell therapies for patients with hematologic malignancies.
 
Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin Lymphoma
KTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.
KTE-C19 Leads to High Response Rates in Refractory NHL
Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.
 
CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated
The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.
Anti-BCMA CAR T-Cell Therapy Approaches 80% Response in Myeloma
An investigational anti-BCMA chimeric antigen receptor T-cell therapy demonstrated an objective response rate of 78% in patients with relapsed/refractory multiple myeloma.
CLL Landscape to Change Dramatically Over Next Decade
Standard treatment approaches for patients with chronic lymphocytic leukemia will continue to include fludarabine, cyclophosphamide, and rituximab and allogeneic stem cell transplantation.
Publication Bottom Border
Border Publication